New drugs for tuberculosis: current status and future prospects.
This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
O'Brien
Richard J
RJ
Foundation for Innovative New Diagnostics, Case Postale 93, 1216 Cointrin/Geneva, Switzerland. rickobrien@finddiagnostics.org
Spigelman
Mel
M
D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents